Search

everythinglearnresearchcommunity

for

Search:↓

Most adverse reactions to the treatment were mild, with nausea being the most common.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

Antizyme slows skin tumor growth by reducing cell growth in mice.

The gel improves hair regrowth and reduces irritation in alopecia areata treatment.

Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.

Melanoma cells lose their ability to form tumors when placed in a zebrafish embryo environment.

Belatacept may be a promising treatment for alopecia areata.

Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

Megavoltage radiation therapy extended survival in rabbits with thymomas, especially in those weighing more than 1.57 kg.

Two cycles of ABVD chemotherapy followed by 20 Gy radiotherapy is the new standard for early-stage Hodgkin lymphoma due to lower toxicity and similar effectiveness.

Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.

Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.